Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials

Published:2018-02-15 Issue:2 Volume:36 Page:463-470
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Mateos Maria-Victoria¹,Goldschmidt Hartmut²,San-Miguel Jesus³,Mikhael Joseph⁴,DeCosta Lucy⁵,Zhou Lifen⁶,Obreja Mihaela⁶,Blaedel Julie⁶,Szabo Zsolt⁷,Leleu Xavier⁸

Affiliation:

1. University Hospital Salamanca; Salamanca Spain

2. Heidelberg Medical University and National Center for Tumor Diseases; Heidelberg Germany

3. Clinica Universidad de Navarra; Pamplona Spain

4. Mayo Clinic; Phoenix AZ USA

5. Amgen Ltd; London UK

6. Amgen Inc.; Thousand Oaks CA USA

7. Amgen GmbH; Zug Switzerland

8. Centre Hospitalier Universitaire de Poitiers; Poitiers France

Funder

The ASPIRE and ENDEAVOR studies were supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary.

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference23 articles.

1. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma;Hideshima;Mol Cancer Ther,2011

2. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition;Meister;Cancer Res,2007

3. From bortezomib to other inhibitors of the proteasome and beyond;Buac;Curr Pharm Des,2013

4. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma;Kuhn;Blood,2007

5. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events;Arastu-Kapur;Clin Cancer Res,2011

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany;Bone Marrow Transplantation;2024-03-14

2. Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.;Haematologica;2024-01-18

3. A rational approach to functional high-risk myeloma;Hematology;2023-12-08

4. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling;Frontiers in Oncology;2023-10-02

5. Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis;Haematologica;2023-08-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3